Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017046232> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2017046232 endingPage "1022" @default.
- W2017046232 startingPage "1019" @default.
- W2017046232 abstract "In hepatitis B or hepatitis C endemic areas, the number of patients with dual infections is substantial. In such patients, interferon-α plus ribavirin can achieve sustained hepatitis C virus (HCV) clearance and hepatitis B e antigen (HBeAg) seroconversion. Pegylated interferon (PegIFN), an established treatment for hepatitis C, is currently increasingly recognized as an efficient therapy for hepatitis B. No case of successful use of PegIFN plus ribavirin has yet been reported, however, in hepatitis B virus (HBV) and HCV coinfection. We report on a 32-year-old man, of Kampuchean origin, with chronic hepatitis B, as documented by the presence of hepatitis B surface antigen with HBeAg, who was coinfected with HCV genotype 1. On therapy with PegIFN-α2b plus ribavirin, HCV RNA became undetectable at week 17. At the end of the 48 weeks of treatment, HCV RNA was still undetectable, HBV DNA was reduced and HBeAg remained positive. Twelve weeks after the end of treatment, HBV DNA reduction was followed by HBeAg to anti-HBe seroconversion. Two years after the end of treatment, HCV RNA and HBV DNA were still undetectable, and HBeAg to anti-HBe seroconversion was maintained. We conclude that the combination of PegIFN plus ribavirin may induce suppression of both viral infections." @default.
- W2017046232 created "2016-06-24" @default.
- W2017046232 creator A5004454710 @default.
- W2017046232 creator A5009032052 @default.
- W2017046232 creator A5013246678 @default.
- W2017046232 creator A5031172542 @default.
- W2017046232 creator A5044500021 @default.
- W2017046232 creator A5085912537 @default.
- W2017046232 date "2006-09-01" @default.
- W2017046232 modified "2023-10-18" @default.
- W2017046232 title "Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-??2b plus ribavirin treatment in a patient with hepatitis B and C coinfection" @default.
- W2017046232 cites W1532462760 @default.
- W2017046232 cites W1556420049 @default.
- W2017046232 cites W1784997902 @default.
- W2017046232 cites W1809351441 @default.
- W2017046232 cites W1978339383 @default.
- W2017046232 cites W2008517556 @default.
- W2017046232 cites W2027545702 @default.
- W2017046232 cites W2033712837 @default.
- W2017046232 cites W2047208492 @default.
- W2017046232 cites W2090852043 @default.
- W2017046232 cites W2095541672 @default.
- W2017046232 cites W2103116252 @default.
- W2017046232 cites W2127685726 @default.
- W2017046232 cites W2165889558 @default.
- W2017046232 cites W2169631718 @default.
- W2017046232 doi "https://doi.org/10.1097/01.meg.0000224479.97169.e8" @default.
- W2017046232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16894318" @default.
- W2017046232 hasPublicationYear "2006" @default.
- W2017046232 type Work @default.
- W2017046232 sameAs 2017046232 @default.
- W2017046232 citedByCount "16" @default.
- W2017046232 countsByYear W20170462322012 @default.
- W2017046232 countsByYear W20170462322014 @default.
- W2017046232 countsByYear W20170462322017 @default.
- W2017046232 crossrefType "journal-article" @default.
- W2017046232 hasAuthorship W2017046232A5004454710 @default.
- W2017046232 hasAuthorship W2017046232A5009032052 @default.
- W2017046232 hasAuthorship W2017046232A5013246678 @default.
- W2017046232 hasAuthorship W2017046232A5031172542 @default.
- W2017046232 hasAuthorship W2017046232A5044500021 @default.
- W2017046232 hasAuthorship W2017046232A5085912537 @default.
- W2017046232 hasConcept C159047783 @default.
- W2017046232 hasConcept C203014093 @default.
- W2017046232 hasConcept C2522874641 @default.
- W2017046232 hasConcept C2775940106 @default.
- W2017046232 hasConcept C2776408679 @default.
- W2017046232 hasConcept C2776461080 @default.
- W2017046232 hasConcept C2777382497 @default.
- W2017046232 hasConcept C2777410769 @default.
- W2017046232 hasConcept C2777451964 @default.
- W2017046232 hasConcept C2777813720 @default.
- W2017046232 hasConcept C2780040827 @default.
- W2017046232 hasConcept C2780593183 @default.
- W2017046232 hasConcept C71924100 @default.
- W2017046232 hasConceptScore W2017046232C159047783 @default.
- W2017046232 hasConceptScore W2017046232C203014093 @default.
- W2017046232 hasConceptScore W2017046232C2522874641 @default.
- W2017046232 hasConceptScore W2017046232C2775940106 @default.
- W2017046232 hasConceptScore W2017046232C2776408679 @default.
- W2017046232 hasConceptScore W2017046232C2776461080 @default.
- W2017046232 hasConceptScore W2017046232C2777382497 @default.
- W2017046232 hasConceptScore W2017046232C2777410769 @default.
- W2017046232 hasConceptScore W2017046232C2777451964 @default.
- W2017046232 hasConceptScore W2017046232C2777813720 @default.
- W2017046232 hasConceptScore W2017046232C2780040827 @default.
- W2017046232 hasConceptScore W2017046232C2780593183 @default.
- W2017046232 hasConceptScore W2017046232C71924100 @default.
- W2017046232 hasIssue "9" @default.
- W2017046232 hasLocation W20170462321 @default.
- W2017046232 hasLocation W20170462322 @default.
- W2017046232 hasOpenAccess W2017046232 @default.
- W2017046232 hasPrimaryLocation W20170462321 @default.
- W2017046232 hasRelatedWork W2004479501 @default.
- W2017046232 hasRelatedWork W2009634266 @default.
- W2017046232 hasRelatedWork W2045556878 @default.
- W2017046232 hasRelatedWork W2067034737 @default.
- W2017046232 hasRelatedWork W2078888723 @default.
- W2017046232 hasRelatedWork W2108648362 @default.
- W2017046232 hasRelatedWork W2318824964 @default.
- W2017046232 hasRelatedWork W2321188506 @default.
- W2017046232 hasRelatedWork W2977427228 @default.
- W2017046232 hasRelatedWork W4229934245 @default.
- W2017046232 hasVolume "18" @default.
- W2017046232 isParatext "false" @default.
- W2017046232 isRetracted "false" @default.
- W2017046232 magId "2017046232" @default.
- W2017046232 workType "article" @default.